Alembic Pharma Receives USFDA Approval for Heart Disease Drug
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ticagrelor Tablets, 60 mg.
The company announced this development, marking a significant milestone in its pharmaceutical endeavors.
No specific quote is available in the given text.
Ruchika Sharma, a correspondent for Medical Dialogue, reported on this update, covering the pharmaceutical field, policy, and business healthcare news.
Alembic Pharmaceuticals Limited: received USFDA approval for Ticagrelor Tablets.
- Company: Alembic Pharmaceuticals Limited
- Approval: USFDA for Ticagrelor Tablets, 60 mg
Author summary: Alembic Pharma gets USFDA nod for heart drug.
More News
- 'Putin's Pet!' Nigel Farage Heckled Repeatedly While Proposing ECHR Withdrawal In Commons
- Microsoft Azure is down, affecting 365, Xbox, Minecraft, and others | TechCrunch
- The ECHR: legal and political fault lines
- Afghanistan News Today – Breaking News, Politics, Sports & Live Updates | Ariana News
- Top batters dismissed for zero as Zimbabwe suffer disappointing T-20 loss to Afghanistan – Nehanda Radio
- Eastpointe Military Museum building turns 70
- ‘TPL race to Gold Masters Tourney 2025’ to empower young talent across the nation
- Lorient v PSG: Confirmed line-ups as Ballon d'Or winner Dembele returns
- The Sixers appeared to finally run out of energy. Then, Adem Bona happened
- Game Time Thread: Juventus vs. Udinese